Get the Stockscreener App
1.92
3.03%
-0.06
After Hours:
1.97
0.05
+2.60%
Serina Therapeutics Inc stock is traded at $1.92, with a volume of 97,958.
It is down -3.03% in the last 24 hours and down -2.54% over the past month.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
See More
Previous Close:
$1.98
Open:
$2
24h Volume:
97,958
Relative Volume:
0.03
Market Cap:
$28.80M
Revenue:
$130.00K
Net Income/Loss:
$-19.22M
P/E Ratio:
-1.0134
EPS:
-1.8946
Net Cash Flow:
$-18.01M
1W Performance:
+19.25%
1M Performance:
-2.54%
6M Performance:
-50.90%
1Y Performance:
-67.18%
1-Day Range:
$1.8515
$2.00
1-Week Range:
$1.5502
$2.03
52-Week Range:
$1.22
$7.92
Serina Therapeutics Inc Stock (SER) Company Profile
Name
Serina Therapeutics Inc
Sector
Industry
Phone
(256) 327-9630
Address
601 GENOME WAY, HUNTSVILLE
Compare SER vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
1.92 | 29.70M | 130.00K | -19.22M | -18.01M | -1.8946 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Serina Therapeutics Inc Stock (SER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
Serina Therapeutics Inc Stock (SER) Latest News
Serina Therapeutics (SER) SVP granted 85,558 stock options at $1.89 - Stock Titan
Serina Therapeutics (SER) CEO awarded 380,825 stock options - Stock Titan
Serina Therapeutics (SER) CFO awarded 123,019 stock options at $1.89 - Stock Titan
Serina Therapeutics (SER) CSO receives 85,558 stock options at $1.89 strike - Stock Titan
Serina Therapeutics director Karen Wilson buys $37,000 in shares - Investing.com
Serina Therapeutics director Karen Wilson buys $37,000 in shares By Investing.com - Investing.com Australia
Director boosts stake in Serina Therapeutics (SER) with 20K-share buy - Stock Titan
Serina Therapeutics Inc (SER) Q1 2026 Earnings: EPS Miss Amid Continued Development ProgressFinancial Summary - Newser
Serina Therapeutics Q1 2026 Earnings: EPS Misses Estimates as Stock Climbs Despite LossGAAP Earnings Report - Newser
Serina Therapeutics Inc. (SER) Recovers 4.93% as Stock Approaches Key Resistance at $2.08Volume Spike Alerts - Newser
Serina Therapeutics Inc. (SER) Gains Nearly 5% as Stock Approaches Key ResistanceTop Analyst Buy Signals - Newser
Director at Serina Therapeutics (SER) makes open-market buy of 12,183 shares - Stock Titan
16.45M Serina shares registered for resale (NYSE: SER) - Stock Titan
Serina Therapeutics : Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi - marketscreener.com
SER Stock Price, Quote & Chart | SERINA THERAPEUTICS INC. (NYSEARCA:SER) - ChartMill
Serina Therapeutics (SER) Gets a Buy from JonesTrading - The Globe and Mail
Insider-Backed PIPE Deal May Dilute Serina Therapeutics Shareholders and Heighten Governance Risks - The Globe and Mail
Serina Therapeutics (SER) stock surges over 39% after hours—here's why - MSN
Serina Therapeutics 1Q Loss/Shr 58c >SER - Moomoo
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Parkinson's drug trial moves ahead as Serina adds $21.2M funding - Stock Titan
Serina Therapeutics (NYSE: SER) raises $21.2M and advances SER-252 trial - Stock Titan
Serina Therapeutics (NYSE: SER) posts Q1 loss and raises $21.2M PIPE amid cash risk - Stock Titan
Serina Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
SER Technical Analysis | Trend, Signals & Chart Patterns | SERINA THERAPEUTICS INC. (NYSEARCA:SER) - ChartMill
MSN Money - MSN
TradingKey - TradingKey
What Serina Therapeutics (SER) is doing to stay ahead (Slight Loss) 2026-05-08Social Trade Signals - newser.com
How Serina Therapeutics (SER) responds when competition intensifies (Volatility Increases) 2026-05-08Community Buy Alerts - newser.com
The recurring revenue story behind Serina Therapeutics (SER) | Q4 2025: EPS Exceeds ExpectationsPut/Call Ratio - newser.com
Sio Capital (SER) reports 1,000,000 shares, 6.71% stake in Serina Therapeutics - Stock Titan
Serina Therapeutics (SER) Stock: Is It a Strong Investment Pick | Q4 2025: Earnings Beat EstimatesTrending Entry Points - newser.com
Chart Pattern Insight | Serina Therapeutics notches 33% EPS beat, tops loss estimatesPost Earnings - newser.com
Serina Therapeutics (NYSE: SER) seeks share increase and equity plan changes in 2026 proxy - Stock Titan
Serina Therapeutics Inc Stock (SER) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Cap:
|
Volume (24h):